[go: up one dir, main page]

MX2019001320A - Composicion y uso de un peptido. - Google Patents

Composicion y uso de un peptido.

Info

Publication number
MX2019001320A
MX2019001320A MX2019001320A MX2019001320A MX2019001320A MX 2019001320 A MX2019001320 A MX 2019001320A MX 2019001320 A MX2019001320 A MX 2019001320A MX 2019001320 A MX2019001320 A MX 2019001320A MX 2019001320 A MX2019001320 A MX 2019001320A
Authority
MX
Mexico
Prior art keywords
peptide
composition
present
seq
invention further
Prior art date
Application number
MX2019001320A
Other languages
English (en)
Inventor
Carolina Quartim Barbosa Elias Sabbaga Maria
Bezerra De Araujo Christiane
Original Assignee
Fund Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BR102016017666-2A external-priority patent/BR102016017666B1/pt
Application filed by Fund Butantan filed Critical Fund Butantan
Publication of MX2019001320A publication Critical patent/MX2019001320A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composición que comprende un péptido según se define en SEQ ID NO. 1, 3, 4 ó 5 y un vehículo farmacéuticamente aceptable. Uso de un péptido según se define en SEQ ID NO. 1, 3, 4 ó 5 en la manufactura de una composición farmacéutica para tratar enfermedades desatendidas. Método para tratar enfermedades desatendidas.
MX2019001320A 2016-07-29 2017-07-24 Composicion y uso de un peptido. MX2019001320A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102016017666-2A BR102016017666B1 (pt) 2016-07-29 Composição, e, uso de um peptídeo
PCT/BR2017/050210 WO2018018121A1 (en) 2016-07-29 2017-07-24 Composition and use of a peptide

Publications (1)

Publication Number Publication Date
MX2019001320A true MX2019001320A (es) 2019-09-19

Family

ID=59626401

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001320A MX2019001320A (es) 2016-07-29 2017-07-24 Composicion y uso de un peptido.

Country Status (5)

Country Link
AR (1) AR109199A1 (es)
CL (1) CL2019000236A1 (es)
CO (1) CO2019000942A2 (es)
MX (1) MX2019001320A (es)
WO (1) WO2018018121A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909254B (zh) * 2019-05-10 2024-08-20 国家纳米科学中心 抑制肿瘤活性的多肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102014000521B1 (pt) 2014-01-09 2021-05-25 Proteimax Biotecnologia Ltda peptídeo, uso, composição farmacêutica, método in vitro de inibição ou de identificação de células em divisão

Also Published As

Publication number Publication date
CL2019000236A1 (es) 2019-06-07
WO2018018121A1 (en) 2018-02-01
BR102016017666A2 (pt) 2018-02-14
CO2019000942A2 (es) 2019-02-08
AR109199A1 (es) 2018-11-07

Similar Documents

Publication Publication Date Title
MX2021002321A (es) Nuevos metodos.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
MX2021002322A (es) Nuevos metodos.
MX2025009723A (es) Metodos de tratamiento contra adicciones
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
MX2019000346A (es) Metodos y composiciones para el tratamiento del cancer.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2017006372A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX373272B (es) Terapia de combinacion.
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
MX2017002476A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MY185942A (en) Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse
MY205171A (en) Methods of treatment of hypertriglyceridemia
MX2020001928A (es) Proceso para la preparacion de tubulisinas e intermediarios de las mismas.
MX2019001320A (es) Composicion y uso de un peptido.